Itraconazole for Esophageal Cancer
This trial tests if itraconazole, a drug for fungal infections, can help treat esophageal cancer. It targets patients with poor survival rates. The drug works by blocking growth signals in cancer cells. The trial will see if adding itraconazole after standard treatment improves outcomes. Itraconazole is an FDA-approved antifungal agent that has shown promising anticancer activities in recent years.
Popular Filters
Trials for Head And Neck Squamous Cell Carcinoma Patients
Virus Therapy
Photoimmunotherapy + Anti-PD1 for Head and Neck Cancer
This trial tests a new treatment combining a light-sensitive drug and an immune booster for patients with hard-to-treat head and neck or skin cancers. The goal is to see if this combination is safe and effective in shrinking tumors.
Platinum-based Chemotherapy
CACTUX for Head and Neck Cancer
This trial is testing a new cancer treatment called CACTUX. It's a combination of 3 drugs, and the investigators want to see if it's effective and has fewer side effects than the standard treatment.
Monoclonal Antibodies
Cetuximab + Interleukin-12 for Head and Neck Cancer
This trial is testing the side effects and best dose of a combination of two drugs to treat patients with head and neck squamous cell carcinoma that has come back or spread. The two drugs are recombinant interleukin-12 and cetuximab.
Trials for SCC Patients
Procedure
Ascorbic Acid for Skin Cancer
This trial tests a vitamin C solution and an approved cream for treating a specific type of skin cancer in adults. The vitamin C solution aims to kill cancer cells and reduce inflammation, while the cream boosts the immune system to fight cancer. Vitamin C has been studied for its various health benefits.
PARP Inhibitor
Pembrolizumab + Olaparib for Head and Neck Cancer
This trial will test whether using pembrolizumab and olaparib together before and after chemoradiation therapy is more effective in treating locally advanced head and neck squamous cell carcinoma than chemoradiation therapy alone.
Trials for Metastatic Patients
PARP Inhibitor
Pembrolizumab + Olaparib for Head and Neck Cancer
This trial will test whether using pembrolizumab and olaparib together before and after chemoradiation therapy is more effective in treating locally advanced head and neck squamous cell carcinoma than chemoradiation therapy alone.
Virus Therapy
Photoimmunotherapy + Anti-PD1 for Head and Neck Cancer
This trial tests a new treatment combining a light-sensitive drug and an immune booster for patients with hard-to-treat head and neck or skin cancers. The goal is to see if this combination is safe and effective in shrinking tumors.
Trials for P16 Positive Patients
PARP Inhibitor
Pembrolizumab + Olaparib for Head and Neck Cancer
This trial will test whether using pembrolizumab and olaparib together before and after chemoradiation therapy is more effective in treating locally advanced head and neck squamous cell carcinoma than chemoradiation therapy alone.
Palbociclib + Chemoradiation for Head and Neck Cancer
This trial is testing a new cancer treatment that involves taking a drug called palbociclib before and after chemoradiation, to see if it improves outcomes for people with HPV-unrelated head and neck squamous cell carcinoma.
Trials for PD-L1 Positive Patients
Virus Therapy
Photoimmunotherapy + Anti-PD1 for Head and Neck Cancer
This trial tests a new treatment combining a light-sensitive drug and an immune booster for patients with hard-to-treat head and neck or skin cancers. The goal is to see if this combination is safe and effective in shrinking tumors.
Monoclonal Antibodies
Pembrolizumab + Radiation vs Chemotherapy + Radiation for Head and Neck Cancer
This trial is testing pembrolizumab, a monoclonal antibody, in combination with radiation therapy or pembrolizumab alone compared to the usual approach of chemotherapy plus radiation therapy after surgery in treating patients with head and neck squamous cell carcinoma that has come back or patients with a second head and neck cancer that is not from metastasis.
Phase 3 Trials
Immune Response Modifier
Imiquimod Cream for Basal Cell Carcinoma
This trial will compare Imiquimod vs. placebo cream for preventing basal cell carcinoma of the skin on the face. 1630 Veterans at high risk of BCC will be recruited from 17 VA medical centers.
Alkylating agents
Chemotherapy + Bevacizumab for Head and Neck Cancers
This trial is testing chemotherapy with or without bevacizumab to see how well it works in treating patients with head and neck squamous cell carcinoma that has come back or spread to other parts of the body.
PD-1 Inhibitor
Pembrolizumab + Radiotherapy for Head and Neck Cancer
This trial is testing whether adding pembrolizumab to radiotherapy (with or without cisplatin) before and after surgery improves outcomes in people with newly diagnosed, resectable head and neck squamous cell carcinoma.
Trials With No Placebo
Procedure
Ascorbic Acid for Skin Cancer
This trial tests a vitamin C solution and an approved cream for treating a specific type of skin cancer in adults. The vitamin C solution aims to kill cancer cells and reduce inflammation, while the cream boosts the immune system to fight cancer. Vitamin C has been studied for its various health benefits.
PARP Inhibitor
Pembrolizumab + Olaparib for Head and Neck Cancer
This trial will test whether using pembrolizumab and olaparib together before and after chemoradiation therapy is more effective in treating locally advanced head and neck squamous cell carcinoma than chemoradiation therapy alone.
Virus Therapy
Photoimmunotherapy + Anti-PD1 for Head and Neck Cancer
This trial tests a new treatment combining a light-sensitive drug and an immune booster for patients with hard-to-treat head and neck or skin cancers. The goal is to see if this combination is safe and effective in shrinking tumors.
View More Related Trials
Frequently Asked Questions
Introduction to squamous cell carcinoma
What are the top hospitals conducting squamous cell carcinoma research?
Hospitals at the forefront of squamous cell carcinoma research are making significant strides in understanding and treating this form of cancer. In Saint Louis, the Washington University School of Medicine is leading the charge with 11 active clinical trials dedicated to squamous cell carcinoma. While they have only conducted one trial historically, their commitment since recording their first study in 2007 demonstrates a promising future for patients battling this disease. The Memorial Sloan Kettering Cancer Center in New york has also made notable contributions, currently undertaking five ongoing clinical trials and having completed seven previous trials focusing on squamous cell carcinoma since launching their initial investigation in 2007.
Meanwhile, in Houston's esteemed University of Texas MD Anderson Cancer Center, researchers are actively conducting four clinical trials aimed at better understanding and combating squamous cell carcinoma. Despite having just two previous studies under their belt since embarking on this research path back in 2004, the institution's dedication is evident as they continue to explore new treatment options for patients affected by this condition.
Further emphasizing the importance of these efforts is Boston's Dana Farber Cancer Institute where another four current squamous cell carcinoma clinical trials are underway alongside four completed studies dating back to their inaugural trial in 2006—a testament to their continuous pursuit of innovation within oncology research.
Rounding out our list is Charleston's Medical University of South carolina, which may have fewer active and historical clinical trials compared to its counterparts but still plays a crucial role. With three ongoing studies focused on squamous cell carcinoma and one past trial recorded from as recently as 2006, they contribute valuable insights into improving patient outcomes and expanding our knowledge about this particular type of cancer.
These top hospitals exemplify unwavering dedication toward unraveling the mysteries surrounding squamous cell carcinoma; each step taken brings us closer to more effective treatments that can improve lives and ultimately defeat this formidable foe.
Which are the best cities for squamous cell carcinoma clinical trials?
When it comes to squamous cell carcinoma clinical trials, several cities emerge as prominent hubs for research and development. New york leads the pack with 25 active studies exploring treatments like Cemiplimab, Definitive Hypofractionation, and Pembrolizumab 200 mg. Saint Louis closely follows with 22 ongoing trials investigating interventions such as Palbociclib, Pembrolizumab, and Pyrimethamine. Boston also plays a significant role in this field with 17 active studies focusing on therapies like Pembrolizumab and Cemiplimab. Additionally, Houston (16 trials) and Los Angeles (14 trials) contribute to the advancement of knowledge through their respective investigations into potential treatment options for squamous cell carcinoma.
Which are the top treatments for squamous cell carcinoma being explored in clinical trials?
In the realm of squamous cell carcinoma, clinical trials are exploring various treatment options that show promise. Leading the pack is pembrolizumab, currently involved in nine active trials dedicated to this specific type of cancer. Since its first listing in 2014, it has demonstrated potential through eight all-time squamous cell carcinoma trials. Alongside pembrolizumab, durvalumab has caught researchers' attention with three ongoing trials and one all-time trial since being introduced just last year in 2020. Additionally, cetuximab exhibits significant potential with three active and nine all-time squamous cell carcinoma trials since its debut back in 2008. These treatments provide hope for patients battling squamous cell carcinoma as research progresses towards finding more effective solutions to combat this disease.
What are the most recent clinical trials for squamous cell carcinoma?
Recent clinical trials for squamous cell carcinoma offer new hope and potential treatment options for patients. These trials include the evaluation of INCB099280 Dose 1, which has entered Phase 2 and shows promise in combating this type of cancer. Additionally, a combination therapy involving GB1211 and Pembrolizumab is being studied to assess its effectiveness against squamous cell carcinoma. The Reduce Dose without Concurrent Chemotherapy Rapid Responder trial aims to determine if reducing the dose of chemotherapy while maintaining efficacy can benefit patients with this condition. Other ongoing studies such as Single Cohort and Arm 1 are also exploring innovative approaches to better understand and treat squamous cell carcinoma. These advancements highlight the commitment of researchers towards improving outcomes for individuals affected by this disease.
What squamous cell carcinoma clinical trials were recently completed?
A recent completion of a clinical trial brings encouraging news for patients with squamous cell carcinoma. The University of Arizona led an investigation into the efficacy of injecting TVEC directly into target lesions during weeks 1-2. This ground-breaking trial, completed in August 2018, highlights the ongoing efforts to improve treatment options and outcomes for individuals battling this particular type of skin cancer. Though more research is needed, such advancements offer hope and potential breakthroughs in the fight against squamous cell carcinoma.